CYP2J2 and cardiac hypertrophy: In order to exclude the effect of blood pressure lowering by CYP2J2 in the development of cardiac hypertrophy, we used hydralazine (100 mg L−1) to reduce the blood pressure, the effect of which was consistent with CYP2J2 overexpression (Fig. S5A).